Clinical Issues in COVID-19Debates and Discussions About Monoclonal Antibody Therapies
This activity is intended for infectious disease, internal medicine, and other clinicians involved in the management of patients with mild or moderate coronavirus disease (COVID-19) who are at risk for clinical progression.
A panel of experts will discuss a series of educational topics related to the stratification of patients with COVID-19 based on risks of disease progression, current evidence and regulatory status for anti-SARS-CoV-2 monoclonal antibodies, and how to best utilize these treatment options to maximize patient outcomes and reduce health disparities.
After completing this activity, the participant should be better able to:
- Describe the clinical profiles and trial data for current and emerging anti-SARS-CoV-2 monoclonal antibodies
- Identify patients with mild-to-moderate COVID-19 who are at high risk for clinical progression
- Treat patients who qualify for anti-SARS-CoV-2 monoclonal antibody therapy based on current guidelines from the US Food and Drug Administration
- Reduce barriers to the use of anti-SARS-CoV-2 monoclonal antibody therapies, including patient reluctance and healthcare disparities
- What is the Current Status of Anti-SARS-CoV-2 Monoclonal Antibodies?
- Who Should Be Treated With Anti-SARS-CoV-2 Monoclonal Antibodies?
- How Do We Use Anti-SARS-CoV-2 Monoclonal Antibodies in Real-World Practice?
- Where Are We Going With Anti-SARS-CoV-2 Monoclonal Antibodies?
- How Can We Reduce Disparities in the Use of Anti-SARS-CoV-2 Monoclonal Antibodies?
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioner Continuing Education
This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitionres as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 2.0 contact hour(s) (which includes xx hours of pharmacology).
Pharmacology hour(s) TBD after clinical content review.
Pharmacist Accreditation Statement
Global is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global designates this continuing education activity for 2.0 contact hours (0.20 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number - 0530-9999-21-164-L01-P). This is an application-based activity.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must participate in the virtual event and complete the program post-test and evaluation. For ACPE learners, please check the CPE monitor for your CE credit within 60 days of the activity.
Disclosure of Conflicts of Interest
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or email@example.com.
Integritas Contact Information
For any other questions about this program, please contact Mara Simpson at firstname.lastname@example.org.
This activity is jointly provided by Global Education Group and Integritas Communications
This activity is supported by an educational grant from AstraZeneca.